Novavax, FDA and COVID
Novavax’s stock slides 19% after FDA puts clinical hold on COVID and flu vaccine candidates
Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu vaccine candidates, following a case of motor neuropathy in a participant in a mid-stage trial.
US FDA pauses Novavax's trial of combo COVID-flu shot on safety concerns
The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu vaccines after a participant who took the combination shot reported nerve damage, the company said on Wednesday.
Novavax Stock Plunges After FDA Pauses Covid, Flu Vaccine Trials
Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined Covid-flu vaccine and standalone flu inoculation due to safety concerns. Fi
FDA puts Novavax's phase 3 plan for pair of vaccine programs on hold over nerve disease case
Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu programs on hold in response to a case of nerve disease from a former parti | The phase 2 trial wrapped up in July 2023,
Novavax says FDA put hold on combination Covid-flu shot and influenza vaccine; shares plunge
The so-called clinical hold is due to a single report of nerve damage in a patient who received the combination shot in a phase two trial.
Novavax Says FDA Puts Clinical Hold on Covid-19, Flu Vaccines
Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and standalone flu inoculation, sending shares down sharply.
Business Wire3h
NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Novavax, Inc. and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...
How Bad Is This News for Novavax?
How bad is this news for Novavax? Let's find out. Image source: Getty Images.
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Novavax’s Regulatory Setback and Mid-Term Underperformance: An Analyst’s Perspective
Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.
Daily3d
Novavax faces setback as USFDA halts COVID-Flu vaccine trial over nerve damage report
Novavax said a participant enrolled in a mid stage study of the combination vaccine last month reported symptoms of motor ...
Novavax gets EU authorization for updated COVID vaccine targeting JN.1 strain
The European Commission authorized Novavax's updated COVID-19 vaccine targeting the JN.1 strain of coronavirus in the region, ...
Yahoo Finance2d
Novavax, Inc. (NVAX)
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has placed a ...
Robinhood, Novavax, Phunware, Lucid Group, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Wednesday, major U.S. indices saw gains, with the Dow Jones Industrial Average climbing nearly 0.8% to 43,077.70.